Microfluidics: A focus on improved cancer targeted drug delivery systems

Pharmaceutical science aims to localize the pharmacological activity of the drug at the site of action. Targeted drug delivery systems can directly deliver the payload to the desired site of action without undesired interaction with normal cells. This is especially important for anticancer drugs to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of controlled release 2013-12, Vol.172 (3), p.1065-1074
Hauptverfasser: Khan, Ikram Ullah, Serra, Christophe A., Anton, Nicolas, Vandamme, Thierry
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1074
container_issue 3
container_start_page 1065
container_title Journal of controlled release
container_volume 172
creator Khan, Ikram Ullah
Serra, Christophe A.
Anton, Nicolas
Vandamme, Thierry
description Pharmaceutical science aims to localize the pharmacological activity of the drug at the site of action. Targeted drug delivery systems can directly deliver the payload to the desired site of action without undesired interaction with normal cells. This is especially important for anticancer drugs to avoid side effects and improve therapeutic response and patient compliance. Number of targeted drug delivery systems for anticancer drugs are in market and many more are in research phase. Most of the methods so far used suffer from poor drug loading, variation in composition, attachment of targeting ligands to carriers, and in vivo and in vitro cellular uptake in cancer cell. Recently microfluidic techniques are gaining attention from researchers and formulation scientists due to the ability of having a better control over the above said parameters not to mention saving cost, material, time and the possibility offered to synthesize different system morphologies from nano to microscale. This article reviews the recent advances in the design of various targeted systems obtained through microfluidics and to some extent addresses challenges and hurdles faced during cancer cell treatment. [Display omitted]
doi_str_mv 10.1016/j.jconrel.2013.07.028
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1516743297</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365913004380</els_id><sourcerecordid>1516743297</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-aee6d41ad6f60e0014ce893b49d1a24055d5ef390071498cf3a060a792bb1d5e3</originalsourceid><addsrcrecordid>eNqFkEtP3DAQgK2qqCy0PwHIsZeE8TvmUiEEpRJVD8DZ8tqTlVfJBuxkpf33NdqFK6fRaL55fYScUWgoUHW5btZ-3CTsGwaUN6AbYO0XsqCt5rUwRn4li8K1NVfSHJOTnNcAILnQ38gx44ZzycSC3P-NPo1dP8cQfb6qrqtu9HOuxk0Vh5c0bjFU3m08pmpyaYVTyUOaV1XAPm4x7aq8yxMO-Ts56lyf8cchnpLnu9unm_v64d_vPzfXD7UXjE21Q1RBUBdUpwABqPDYGr4UJlDHBEgZJHbcAGgqTOs77kCB04Ytl7SU-Cn5uZ9bjnudMU92iNlj37sNjnO2VFKlBWdGf44KpbgWQoqCyj1aZOScsLMvKQ4u7SwF--bbru3Bt33zbUHb4rv0nR9WzMsBw0fXu-ACXOyBzo3WrVLM9vmxTJDlda25hkL82hNYrG0jJpt9xGI8xIR-smGMnxzxH-LDnH0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1466374454</pqid></control><display><type>article</type><title>Microfluidics: A focus on improved cancer targeted drug delivery systems</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Khan, Ikram Ullah ; Serra, Christophe A. ; Anton, Nicolas ; Vandamme, Thierry</creator><creatorcontrib>Khan, Ikram Ullah ; Serra, Christophe A. ; Anton, Nicolas ; Vandamme, Thierry</creatorcontrib><description>Pharmaceutical science aims to localize the pharmacological activity of the drug at the site of action. Targeted drug delivery systems can directly deliver the payload to the desired site of action without undesired interaction with normal cells. This is especially important for anticancer drugs to avoid side effects and improve therapeutic response and patient compliance. Number of targeted drug delivery systems for anticancer drugs are in market and many more are in research phase. Most of the methods so far used suffer from poor drug loading, variation in composition, attachment of targeting ligands to carriers, and in vivo and in vitro cellular uptake in cancer cell. Recently microfluidic techniques are gaining attention from researchers and formulation scientists due to the ability of having a better control over the above said parameters not to mention saving cost, material, time and the possibility offered to synthesize different system morphologies from nano to microscale. This article reviews the recent advances in the design of various targeted systems obtained through microfluidics and to some extent addresses challenges and hurdles faced during cancer cell treatment. [Display omitted]</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2013.07.028</identifier><identifier>PMID: 23933524</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Active and passive targeting ; adverse effects ; Animals ; antineoplastic agents ; Antineoplastic Agents - administration &amp; dosage ; Antineoplastic Agents - therapeutic use ; Cancer therapy ; cost effectiveness ; Drug Carriers - chemistry ; drug delivery systems ; Drug Delivery Systems - instrumentation ; Drug Delivery Systems - methods ; Equipment Design ; Humans ; markets ; Microchannel ; Microfluidic Analytical Techniques - instrumentation ; Microfluidic Analytical Techniques - methods ; Microfluidics ; Nanocarriers ; Nanostructures - chemistry ; Neoplasms - drug therapy ; patient compliance ; Targeted drug delivery</subject><ispartof>Journal of controlled release, 2013-12, Vol.172 (3), p.1065-1074</ispartof><rights>2013 Elsevier B.V.</rights><rights>2013.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-aee6d41ad6f60e0014ce893b49d1a24055d5ef390071498cf3a060a792bb1d5e3</citedby><cites>FETCH-LOGICAL-c422t-aee6d41ad6f60e0014ce893b49d1a24055d5ef390071498cf3a060a792bb1d5e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jconrel.2013.07.028$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27928,27929,45999</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23933524$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Khan, Ikram Ullah</creatorcontrib><creatorcontrib>Serra, Christophe A.</creatorcontrib><creatorcontrib>Anton, Nicolas</creatorcontrib><creatorcontrib>Vandamme, Thierry</creatorcontrib><title>Microfluidics: A focus on improved cancer targeted drug delivery systems</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>Pharmaceutical science aims to localize the pharmacological activity of the drug at the site of action. Targeted drug delivery systems can directly deliver the payload to the desired site of action without undesired interaction with normal cells. This is especially important for anticancer drugs to avoid side effects and improve therapeutic response and patient compliance. Number of targeted drug delivery systems for anticancer drugs are in market and many more are in research phase. Most of the methods so far used suffer from poor drug loading, variation in composition, attachment of targeting ligands to carriers, and in vivo and in vitro cellular uptake in cancer cell. Recently microfluidic techniques are gaining attention from researchers and formulation scientists due to the ability of having a better control over the above said parameters not to mention saving cost, material, time and the possibility offered to synthesize different system morphologies from nano to microscale. This article reviews the recent advances in the design of various targeted systems obtained through microfluidics and to some extent addresses challenges and hurdles faced during cancer cell treatment. [Display omitted]</description><subject>Active and passive targeting</subject><subject>adverse effects</subject><subject>Animals</subject><subject>antineoplastic agents</subject><subject>Antineoplastic Agents - administration &amp; dosage</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer therapy</subject><subject>cost effectiveness</subject><subject>Drug Carriers - chemistry</subject><subject>drug delivery systems</subject><subject>Drug Delivery Systems - instrumentation</subject><subject>Drug Delivery Systems - methods</subject><subject>Equipment Design</subject><subject>Humans</subject><subject>markets</subject><subject>Microchannel</subject><subject>Microfluidic Analytical Techniques - instrumentation</subject><subject>Microfluidic Analytical Techniques - methods</subject><subject>Microfluidics</subject><subject>Nanocarriers</subject><subject>Nanostructures - chemistry</subject><subject>Neoplasms - drug therapy</subject><subject>patient compliance</subject><subject>Targeted drug delivery</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtP3DAQgK2qqCy0PwHIsZeE8TvmUiEEpRJVD8DZ8tqTlVfJBuxkpf33NdqFK6fRaL55fYScUWgoUHW5btZ-3CTsGwaUN6AbYO0XsqCt5rUwRn4li8K1NVfSHJOTnNcAILnQ38gx44ZzycSC3P-NPo1dP8cQfb6qrqtu9HOuxk0Vh5c0bjFU3m08pmpyaYVTyUOaV1XAPm4x7aq8yxMO-Ts56lyf8cchnpLnu9unm_v64d_vPzfXD7UXjE21Q1RBUBdUpwABqPDYGr4UJlDHBEgZJHbcAGgqTOs77kCB04Ytl7SU-Cn5uZ9bjnudMU92iNlj37sNjnO2VFKlBWdGf44KpbgWQoqCyj1aZOScsLMvKQ4u7SwF--bbru3Bt33zbUHb4rv0nR9WzMsBw0fXu-ACXOyBzo3WrVLM9vmxTJDlda25hkL82hNYrG0jJpt9xGI8xIR-smGMnxzxH-LDnH0</recordid><startdate>20131228</startdate><enddate>20131228</enddate><creator>Khan, Ikram Ullah</creator><creator>Serra, Christophe A.</creator><creator>Anton, Nicolas</creator><creator>Vandamme, Thierry</creator><general>Elsevier B.V</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20131228</creationdate><title>Microfluidics: A focus on improved cancer targeted drug delivery systems</title><author>Khan, Ikram Ullah ; Serra, Christophe A. ; Anton, Nicolas ; Vandamme, Thierry</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-aee6d41ad6f60e0014ce893b49d1a24055d5ef390071498cf3a060a792bb1d5e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Active and passive targeting</topic><topic>adverse effects</topic><topic>Animals</topic><topic>antineoplastic agents</topic><topic>Antineoplastic Agents - administration &amp; dosage</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer therapy</topic><topic>cost effectiveness</topic><topic>Drug Carriers - chemistry</topic><topic>drug delivery systems</topic><topic>Drug Delivery Systems - instrumentation</topic><topic>Drug Delivery Systems - methods</topic><topic>Equipment Design</topic><topic>Humans</topic><topic>markets</topic><topic>Microchannel</topic><topic>Microfluidic Analytical Techniques - instrumentation</topic><topic>Microfluidic Analytical Techniques - methods</topic><topic>Microfluidics</topic><topic>Nanocarriers</topic><topic>Nanostructures - chemistry</topic><topic>Neoplasms - drug therapy</topic><topic>patient compliance</topic><topic>Targeted drug delivery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khan, Ikram Ullah</creatorcontrib><creatorcontrib>Serra, Christophe A.</creatorcontrib><creatorcontrib>Anton, Nicolas</creatorcontrib><creatorcontrib>Vandamme, Thierry</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khan, Ikram Ullah</au><au>Serra, Christophe A.</au><au>Anton, Nicolas</au><au>Vandamme, Thierry</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Microfluidics: A focus on improved cancer targeted drug delivery systems</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2013-12-28</date><risdate>2013</risdate><volume>172</volume><issue>3</issue><spage>1065</spage><epage>1074</epage><pages>1065-1074</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><abstract>Pharmaceutical science aims to localize the pharmacological activity of the drug at the site of action. Targeted drug delivery systems can directly deliver the payload to the desired site of action without undesired interaction with normal cells. This is especially important for anticancer drugs to avoid side effects and improve therapeutic response and patient compliance. Number of targeted drug delivery systems for anticancer drugs are in market and many more are in research phase. Most of the methods so far used suffer from poor drug loading, variation in composition, attachment of targeting ligands to carriers, and in vivo and in vitro cellular uptake in cancer cell. Recently microfluidic techniques are gaining attention from researchers and formulation scientists due to the ability of having a better control over the above said parameters not to mention saving cost, material, time and the possibility offered to synthesize different system morphologies from nano to microscale. This article reviews the recent advances in the design of various targeted systems obtained through microfluidics and to some extent addresses challenges and hurdles faced during cancer cell treatment. [Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>23933524</pmid><doi>10.1016/j.jconrel.2013.07.028</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0168-3659
ispartof Journal of controlled release, 2013-12, Vol.172 (3), p.1065-1074
issn 0168-3659
1873-4995
language eng
recordid cdi_proquest_miscellaneous_1516743297
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Active and passive targeting
adverse effects
Animals
antineoplastic agents
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - therapeutic use
Cancer therapy
cost effectiveness
Drug Carriers - chemistry
drug delivery systems
Drug Delivery Systems - instrumentation
Drug Delivery Systems - methods
Equipment Design
Humans
markets
Microchannel
Microfluidic Analytical Techniques - instrumentation
Microfluidic Analytical Techniques - methods
Microfluidics
Nanocarriers
Nanostructures - chemistry
Neoplasms - drug therapy
patient compliance
Targeted drug delivery
title Microfluidics: A focus on improved cancer targeted drug delivery systems
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T13%3A49%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Microfluidics:%20A%20focus%20on%20improved%20cancer%20targeted%20drug%20delivery%20systems&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Khan,%20Ikram%20Ullah&rft.date=2013-12-28&rft.volume=172&rft.issue=3&rft.spage=1065&rft.epage=1074&rft.pages=1065-1074&rft.issn=0168-3659&rft.eissn=1873-4995&rft_id=info:doi/10.1016/j.jconrel.2013.07.028&rft_dat=%3Cproquest_cross%3E1516743297%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1466374454&rft_id=info:pmid/23933524&rft_els_id=S0168365913004380&rfr_iscdi=true